A型肉毒毒素 (Anterios, Inc.)(Botulinum toxin A(Anterios, Inc.))

概要

基本信息

药物类型

毒素

别名

Botulinum toxin A topical

靶点

SNAP25

作用方式

抑制剂

作用机制

SNAP25 抑制剂(突触相关蛋白25 抑制剂)

治疗领域

皮肤和肌肉骨骼疾病其他疾病

在研适应症-

非在研适应症

寻常痤疮鱼尾纹外眦皱纹+ [1]

原研机构

Anterios, Inc.

在研机构-

非在研机构

Anterios, Inc.Allergan UC

权益机构-

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

8

项与 A型肉毒毒素 (Anterios, Inc.) 相关的临床试验

IRCT20220121053776N1

/ Recruiting临床2/3期

Evaluation of the efficacy, safety, satisfaction and tolerability of treatment with diluted botulinum toxin A in comparison with intralesional triamcinolone in patients undergone PDL laser for Hypertrophic erythematous scars: A blinded randomized controlled clinical trial

开始日期2022-02-20

申办/合作机构

Iran University of Medical Sciences & Health Services

ChiCTR1800019282

/ SuspendedN/AIIT

A randomized, open label, parallel controlled trial for botulinum toxin A injection combined with minoxidil in the treatment of androgenic alopecia

开始日期2018-11-16

申办/合作机构

上海市同济医院

EUCTR2017-003117-25-AT

/ Not yet recruiting临床4期IIT

Longitudinal chemodenervation effects of botulinum toxin A after intramuscular application and the impact of physical activity - BoNT- physical activity and chemodenervation

开始日期2018-05-17

申办/合作机构

Medical University of Vienna

100 项与 A型肉毒毒素 (Anterios, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 A型肉毒毒素 (Anterios, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 A型肉毒毒素 (Anterios, Inc.) 相关的专利（医药）

登录后查看更多信息

2

项与 A型肉毒毒素 (Anterios, Inc.) 相关的文献（医药）

2012-11-01·Journal of Orthopaedic Science

Letter regarding “Effects of botulinum toxin A on fracture healing in rats: an experimental study”

Letter

作者: Tae Hwan Park

Dear EditorI read with great interest the article by Aydin et al. [1]entitled ‘‘Effects of botulinum toxin A on fracture healingin rats: an experimental study’’ and I congratulate theauthors on their interesting experiment. The authorsaddress an important area of investigation.I totally agree that the beneﬁcial effects of botulinumtoxin A in fracture healing can be explained by a paralyticimmobilization effect, which may contribute to nonrigidﬁxation [1]. As you mentioned, this is also true of man-dibular condylar fractures, because mastication musclesaggravate the initial displacement. Injection of botulinumtoxin A into the mastication muscle induces immobiliza-tion of the muscle, leading to better fracture healing.As we know, angiogenesis is crucial for appropriatefracture healing. Although there has been some controversyover the effects of botulinum toxin A on angiogenesis,recent studies showed botulinum toxin A had little effecton angiogenesis [2, 3].Haubner et al. could not identify any effect of botulinumtoxin A on endothelial cells in respect of synthesis ofthe tested cytokines and growth factors. They concludethat their in-vitro study does not add evidence to suggesta signiﬁcant therapeutic effect of botulinum toxinA injections on cutaneous wound healing beyondchemoimmobilization.Regarding dosage of botulinum toxin A, have theauthors performed a pilot study with different dosages? Ibelieve the dose of 8 units of botulinum toxin A is insuf-ﬁcient to enable fracture healing.Without doubt, further studies are warranted to betterclarify the effect of botulinum toxin A on the fracture-healing process.

1999-04-09·European Journal of Pediatrics

Lack of response to botulinum toxin A in patients with hypertrophic pyloric stenosis

Letter

作者: R. Korinthenberg ; P. Greiner ; M. Brandis ; F. Heinen ; V. Mall ; K. D. Rückauer ; J. Sontheimer

Received: 8 September 1998 /Accepted in revised form:16 September 1998Sir: Intramuscular injection of botulinum toxin A is an e•ectivetherapy for children and adults with dystonic and spastic move-ment disorders as well as with achalasia [2, 3, 4]. We report on theuse of botulinum toxin in two infants with hypertrophic pyloricstenosis, neither of whom responded to this treatment. Our resultssuggest that: (1) botulinum toxin A is not a treatment option inhypertrophic pyloric stenosis in infants and (2) the release ofacetylcholine does not play a major role in the pathophysiology ofthis condition.Two unrelated infants (a 3-week-old male and a 5-week-oldfemale) were diagnosed with hypertrophic pyloric stenosis, con-ﬁrmed by ultrasound. Following approval by the Ethics committee(Freiburg University) and by the parents who were informed aboutthe experimental nature of this therapy, botulinum toxin A wasdelivered into the pyloric muscle using a ﬂexible, upper gastro-intestinal, endoscopically-guided injection. The dose of botulinumtoxin A was adapted from previous experience in patients withdystonic conditions for the ﬁrst patient (5 U Dysport/kg bodyweight; total 20 U) and patients with spasticity for the secondpatient (12 U Botox/kg body weight, total 44 U).Neither patient showed either clinical or sonographic responseto treatment during the following 4 days, although this periodshould have been su†cient to achieve a detectable e•ect. Correctadministration application was conﬁrmed by reviewing videorecordings of the procedure. The given dose used for our secondpatient was the same as that used e•ectively for the treatment ofchildren with achalasia [3]. In both of our patients surgicalintervention (Ramstedt procedure) was performed with a successfuloutcome.Acetylcholine is considered to be the primary neurotransmitterwith excitatory e•ects upon smooth muscle [1]. In achalasia the lossor dysfunction of inhibitory neurons which contain vasoactivepolypeptide and nitric oxide results in a predominantly excitatorycholinergic innervation that can be suppressed by botulinum toxinA [4]. In hypertrophic pyloric stenosis the inability to relax thepyloric muscle has been considered to be due to deﬁciency of nitricoxide synthetase [5]. The lack of e•ect of botulinum toxin Asuggests that the gastric outlet obstruction in hypertrophic pyloricstenosis is not due to a predominantly cholinergic excitatoryinnervation. Instead, hypertrophic pyloric stenosis could be causedby development-related denervation a•ecting both inhibitory andexcitatory pathways.

100 项与 A型肉毒毒素 (Anterios, Inc.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	A型肉毒毒素 (Anterios, Inc.)	-	DB00083

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
原发性腋窝多汗症	临床2期	美国	Allergan UC	2015-06-03
鱼尾纹	临床2期	美国	Anterios, Inc.	2011-05-01
外眦皱纹	临床2期	美国	Anterios, Inc.	2011-05-01
寻常痤疮	临床2期	美国	Anterios, Inc.	2011-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02479139 (CTgov)	临床2期	原发性腋窝多汗症	145	Vehicle (Vehicle)	願醖觸範鑰窪醖廠醖網(網鬱襯簾窪選夢窪獵鹹) = 遞選構獵艱壓膚壓窪構顧簾顧鹹鑰餘衊獵願繭 (製壓鏇淵願獵獵醖觸衊, 衊艱醖繭網顧選顧製廠 ~ 夢餘鹹遞積蓋鹹鏇觸願) 更多	-	2017-09-20
				ANT-1207 (ANT-1207 Dose 1)	願醖觸範鑰窪醖廠醖網(網鬱襯簾窪選夢窪獵鹹) = 簾窪鹽艱醖製齋廠醖衊顧簾顧鹹鑰餘衊獵願繭 (製壓鏇淵願獵獵醖觸衊, 齋淵構選製憲窪衊簾簾 ~ 願構鹹獵膚衊膚網襯膚) 更多